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Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in
the rat. Three hours following injection of anti-GBM (glomerular
basement membrane) antibody (10 mg/kg, i.v.) into rats, glomerular
production of LTB4 was significantly increased as compared to un-
treated rats (497 26 vs. 244 18 pg of LTB4/mg protein). Twenty-four
hours following administration of anti-GBM antibody, renal function
(blood urea nitrogen, BUN; plasma creatinine, ncr; creatinine clear-
ance, Ccr; fractional excretion of sodium, FENa; fractionalexcretion of
urea, FEUrCa) was determined to be impaired proportionally to the
amount of injected antibody (5 to 30 mg/kg, i.v.). In a second series of
experiments, a selective 5-lipoxygenase (5-LO) inhibitor, SK&F
107649, was used to investigate the involvement of 5-LO products in the
pathophysiology of anti-GBM antibody-induced glomerulonephritis. In
preliminary experiments, SK&F 107649 (50 to 200 mg/kg, p.o.) inhib-
ited ionophore (A23 187)-stimulated whole blood leukotriene (LT) B4
production in a dose-dependent fashion (P < 0.05 at doses  100
mg/kg). The anti-GBM antibody-mediated decrease in glomerular filtra-
tion rate (GFR) and increase in BUN and P. were dose-dependently
attenuated by SK&F 107649 (50 to 200 mg/kg, p.o. BID). These data
confirm that glomerular LTB4 production is stimulated in anti-GBM
antibody-induced glomerulonephritis, and demonstrate that inhibition
of 5-LO by SK&F 107649 normalizes BUN and C. and attenuate the
decrease in GFR following anti-GBM antibody treatment. These results
provide additional evidence for a role of 5-LO products in immune-
mediated renal disease, and suggest that pharmacologic inhibition of
5-LO may be of therapeutic value.
Experimental glomerulonephritis can be induced in animals
by antibodies directed against the glomerular basement mem-
brane, and is associated with immunologic changes, including
the deposition of antibody, activation of complement, inflam-
matory cell infiltration, and the increased production of cy-
clooxygenase (prostaglandin G/H synthase) and lipoxygenase
products [1—31.
Proteinuria and decreased GFR occur within 24 hours of
anti-GBM antibody injection. Although the causative factors in
the renal dysfunction have not been fully characterized, com-
plement activation is likely to be important, as complement
depletion attenuates the degree of diminished renal function [41,
as well as the PMN infiltration and the elevated glomerular
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production of LTB4, 5-hydroxyeicosatetraenoic (HETE) and
12-HETE [1]. Although the cellular source of the 5-lipoxygen-
ase (5-LO) products is unclear, there is evidence that they may
make an important contribution to the decrease in renal func-
tion. It has been reported that the intrarenal injection of LTB4
or low dose anti-GBM serum has minimal effects on renal
hemodynamics. In the presence of LTB4, however, low dose
anti-GBM serum causes significant renal dysfunction [5].
The current study was performed to characterize the renal
dysfunction produced by anti-GBM antibodies further, and
determine the effects of selective inhibition of 5-LO on the
dysfunction.
Methods
SK&F 107649 (N-hydroxy-N-[l ,2,3,4-tetrahydro-6-(phenyl-
methoxy)-1-naphthalenyl]urea) was prepared by the Depart-
ment of Medicinal Chemistry at SmithKline Beecham Pharma-
ceuticals (King of Prussia, Pennsylvania, USA) (Fig. 1). LTB4
antibody was obtained from Dr. Philip Needleman (Monsanto,
St. Louis, Missouri, USA).
Preparation of anti-GBM antibodies
Sheep anti-GBM antibodies were produced as previously
described [6]. Briefly, sheep were repeatedly immunized with
freshly isolated rat glomeruli which were emulsified in incom-
plete Freund's adjuvant (Defco Labs, Detroit, Michigan). After
repeated immunizations, the sheep developed renal failure
(detected by frequent analysis of BUN) at which time they were
anesthetized, blood was collected, and the animal euthanized.
Serum was obtained, heated to 56°C for one hour to inactive
complement, extensively absorbed with rat erythrocytes, and
filtered (0.45 m) prior to immunoglobulin purification by
affinity column chromotography according to the manufactur-
er's protocol (GammaBind G, Genex Corp., Gaithersburg,
Maryland, USA). The eluted antibody was concentrated by
lyophilization, reconstituted in PBS, filtered and stored at
—70°C. The purity of immunoglobulin was 99% as determined
by gel electrophoresis. Specific binding of the sheep antibody to
rat GBM was indicated by the linear deposition of the antibody
detected by indirect immunofluorescent staining. The concen-
tration of the isolated immunoglobulin was determined spectro-
photometrically at 280 n. Normal sheep antibody (that is,
antibody not stimulated by a specific antigen) was obtained
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Fig. 1. SK&F 107649.
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from sheep that were treated as above, except that normal
saline instead of rat glomeruli were emulsified in the Freund's
adjuvant. Purification and separation of the antiserum and
antibody was identical to that of the anti-GBM antibody.
Anti-GBM antibody and SK&F 107649 administration
In the first series of experiments, male Sprague-Dawley rats
(170 to 200 g) were injected i.v. with 5 to 30mg/kg of anti-GBM
antibody (one dose/rat). Control rats were not injected with
antibody. Rats were housed in metabolic cages for 24 hours
with ad libitum access to food and water. Twenty-four hour
urinary protein excretion was determined by the sulfosalicylic
acid turbidometric method [7]. Serum and urinary electrolytes,
urea nitrogen and creatinine were analyzed on a Monarch 2000
chemistry analyzer (Instrumentation Laboratory, Lexington,
Massachusetts, USA).
In a second series of experiments, the effect of 5-LO inhibi-
tion on anti-GBM-mediated renal dysfunction was determined.
SK&F 107649 (50, 75, 100, 150, 200 mg/kg) was administered
p.o. 30 minutes before and six hours after the injection of
antibody (27 mg/kg, i.v.). In these experiments, control animals
also received the anti-GBM antibody, but were administered
the drug vehicle, 10% dimethylacetamide in sesame seed oil.
In a third series of experiments, another preparation of
antibody was used which was obtained from the same serum
used in the first two sets of experiments, but was isolated from
a different series of affinity column chromatography purification
runs. This preparation of anti-GBM antibody was more neph-
rotoxic, as determined by concentration response experiments.
An 18 mg/kg dose of this antibody resulted in changes in BUN
and 'Cr similar to that obtained with 27 mg/kg of anti-GBM
antibody in the first series of experiments. Thirty-six male
Sprague-Dawley rats were randomly assigned to six groups (6
per group) and treated as follows: uninjected controls (Group
1); rats given drug vehicle, injected i.v. with 18 mg/kg anti-GBM
antibody and killed at 3 (Group 2) or 24 hours (Group 3); rats
given 200 mg/kg SK&F 107649, then injected i.v. with 18 mg/kg
anti-GBM antibody and killed at 3 (Group 4) or 24 hours (Group
5); and rats given vehicle, then injected with 18 mg/kg normal
sheep IgG and killed at 3 hours (Group 6). Rats were anesthe-
tized and kidneys were flushed in situ via retrograde perfusion
of the aorta with saline. The right kidney was collected and a
median transverse slice was snap frozen in cold isopentane
immersed in liquid nitrogen. The frozen tissue was stored at
—80°C for immunofluorescence. The left kidney was fixed by
perfusion with a 2% paraformaldehyde/1% glutaraldehyde so-
lution and a median transverse slice was collected for histology
and quantification of polymorphonuclear cells (PMNs) in gb-
mcmli.
Histopathology
For detection of PMNs, 5 sm paraffin sections were incu-
bated in napthol AS-D choloroacetate esterase staining solution
(Sigma Diagnostics, St. Louis, Missouri, USA) for five hours
and counterstained with Gill's No. 3 hematoxylin. The number
of gbomerular PMNs were quantitated in 50 glomeruli per
section and expressed as the average number of PMNs per
glomerulus.
For immunofluorescence, 10 pm cryostat sections were in-
cubated with monospecific, fluorescein-labeled anti-sheep IgG
(Vector Laboratories, Burlingame, California, USA) or rabbit
anti-rat C3 (Bethyl Laboratories, Montgomery, Texas, USA),
followed by fluorescein-labeled anti-rabbit IgG (Vector Labo-
ratories). The sections were examined in a Nikon fluorescence
microscope and the deposition of the various proteins in gb-
meruli was assessed qualitatively for their distribution pattern,
and the intensity of the staining was assessed semiquantita-
tively using a 0 to 3 + scale.
LTB4 and thromboxane B2 production in rat whole blood
To determine the effect of SK&F 107649 on whole blood
LTB4 production, SK&F 107649 (or its vehicle) was adminis-
tered p.o. to rats at 50, 100, 150, and 200 mg/kg (6 rats per
group). To determine the effect of SK&F 107649 on thrombox-
ane production, 200 mg/kg of SK&F 107649 or its vehicle was
administered p.o. to rats (6 rats per group). Three hours after
compound administration, cardiac blood was collected into
0.01% heparinized containers and incubated for five minutes at
37°C. The calcium ionophore, A23 187 (60 M), was added and
the samples were incubated for 10 minutes at 37°C with con-
stant agitation. Prostaglandin (PG) B2 (1 nmol) was added
followed immediately by ethyleneglycolbis(aminoethyleth-
er)tetra-acetate (EGTA, 10 nM) to stop the reaction. Blood
samples were centrifuged at 400 g for 15 minutes. The plasma
fraction was recovered and a 1 vol of chilled acetonitrile was
added. The mixture was centrifuged at 500 g for 10 minutes at
5°C. LTB4 and thromboxane B2 in the supernatants were
extracted as previously described [8]. Briefly, alter diluting the
acetonitrile to 20% with 1% formic acid and 1% triethylamine,
the samples were loaded onto a preconditioned C18 SPE
cartridge (J.T. Baker Chemical Co., Phillipsburg, New Jersey).
The column was washed with 1% formic acid and 1% triethyl-
amine, then washed again with petroleum ether. The ci-
cosanoids were eluted from the column with methyl formate,
concentrated under vacuum, and resuspended in EIA (Enzyme
Immunoassay) buffer. LTB4 and thromboxane B2 concentration
were determined by EIA for LTB4 and thromboxane B2 accord-
ing to the manufacturer's protocol (Cayman Chemical Co., Ann
Arbor, Michigan, USA). The detection limit for LTB4 in this
assay is 4.9 pg/mI at an 80% B/BO. The cross reactivities of the
LTB4 antibody are 0.3% for 5(S), 12(S) Di-HETE and <0.1%
for 5(S)-HETE, 12(S)-HETE, 12(R)-HETE, LTC4, LTE4,
LTD4, and arachidonic acid. In the thromboxane EIA, the
SK&F 107649
Albrightson et a!: 5-LO inhibition and improved renal function 1303
0)
00
detection limit for thromboxane B2 is 11 pg/mI at an 80% B/B0.
The cross reactivities of the thromboxane B2 antibody are 8.2%
for 2,3-dinor thromboxane B2, 0.4% for PGD2 and <0.2% for
PGF2a, 1 1-dehydro thromboxane B2, PGE2 and LTB4.
Eicosanoid production from human whole blood
Heparinized human blood was collected by venipuncture.
The blood was prewarmed (4.5 ml of blood per sample) for five
minutes at 37°C in a waterbath with constant agitation. A23187
(60 tM) in 0.5 ml autologous plasma was added, and the blood
incubated for 10 minutes at 37°C. PGB2 (1 nmol) was added to
the sample, then the reaction was stopped by placing on ice
followed by centrifugation 2500 x g for 15 minutes at 4°C. The
plasma was collected and combined with 2 ml of ice cold
acetonitrile. This was centrifuged at 2500 x g for 15 minutes,
and the supernatant was added to 6 ml of ice cold 1% formic
acid. The sample was purified by solid phase extraction using a
C18 column (J.T. Baker) and eluted with 3 ml of methyl formate.
The methyl formate was dried down under vacuum, and the
residue resuspended in 300 jsl of 30% acetonitrile buffered with
30 mti ammonium acetate (pH 5.8). The extraction recovery
was >90%.
The sample (200 pi) was loaded onto a reverse-phase column
(RCM NOVA-PAK C18 100 x 8 mm column, Waters Associ-
ates, Milford, Massachusetts, USA). The starting mobile phase
was 90% A [A = 10% acetonitrile buffered with 25 mM
ammonium acetate (pH 5.8)] and 10% B (B = 90% acetonitrile
buffered with 10 msi ammonium acetate). The flow rate for the
separation was 2.5 ml/min. After five minutes, the %B was
increased to 27% in a step fashion. Over the next 10 minutes,
the %B was increased in a concave hyperbolic function to 40%
and then increased in a linear manner to 60% over the next 10
minutes. Under these developing conditions, the retention
times for LTB4 and 12(S)-hydroxyheptadecatrienoic acid
[12(S)-HHT] were 12.5 and 17.2 minutes, respectively.
The column effluent was monitored from 225 to 310 nm using
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Fig. 3. Effect of anti-GBM antibodies on 24-hour urinary protein
excretion (A) and urinary protein excretion corrected for GFR (B). Data
presented are the mean SEM, N  6. In some cases the SaM was small
and obscured by the size of the symbol. *p < 0.05 compared to
controls. Experimental protocol, data presentation and statistics are as
described for Fig. 1.
a UV photodiode array detector. The eicosanoids in the sample
were verified by their retention times and their UV absorbance
spectra. The peaks were quantified by measuring their area of
absorbance at their maximal wavelength of absorbance. This
area was corrected to a mass unit using a standard curve
generated from external standards. The calculated mass was
corrected for the recovery of the internal standard.
Human platelet 12-lipoxygenase assay
Platelets were prepared from fresh human blood collected in
acid citrate dextrose (1:6) as the anticoagulant. Platelet-rich
plasma was prepared by centrifuging the whole blood for 40
minutes at 100 x g, 25°C. The platelet-rich plasma was acidified
to pH 6.5 with 0.15 M citric acid and then centrifuged for 10
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Fig. 2. Effectof anti-GBM antibodies on 24-hour creatinine clearance(Cc,). Data presented are the mean SEM, N  6. In some cases the
5EM was small and obscured by the size of the symbol. p < 0.05
compared to controls.
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Fig. 4. Effect of anti-GBM antibodies on BUN (A) and c, (B).
Twenty-four hours after injection of the indicated concentrations of
anti-GBM antibodies, plasma was obtained and BUN and 'Cr mea-
sured. Data presentation and statistics are as described for Fig. 1.
minutes at 900 x g, 25°C. The pellet was resuspended in
Tyrodes-Hepes buffer, which consists of 137 mM NaCI, 2.8 mM
KC1, 11.9 ifiM NaHCO3, 1 mri MgCl2, 1.4 m CaCI2, and 5 mM
Hepes, pH 7.35. All manipulations of the platelets were per-
formed at room temperature.
The washed platelets (1.5 x 108) were incubated with 2 sM
calcium ionophore A23 187 (0.5 ml final incubation volume) for
10 minutes. At the end of the incubation, 15-HETE (200 pmol)
was added which was followed by the addition of 4 volumes of
ethyl acetate. The organic layer was collected and removed
under vacuum. The residues were resuspended in 300 pi of 50%
methanol and clarified by filtration through a 0.2 m filter.
Samples were loaded onto a reverse-phase column (RCM
NOVA-PAK C18 100 x 5 mm column, Waters Associates)
eluted with a starting mobile phase of 80% (A = 10% acetoni-
trile buffered with 25 mi,,s ammonium acetate) and 20% B (B =
90% acetonitrile buffered with 10 mr'.i ammonium acetate). The
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Fig. 5. Effect of anti-GBM antibodies on FEore (A) and FEND (B).
FEur and FENa were calculated from parameters measured in the
24-hour urine sample and in the plasma. Data presentation and statistics
are as described in Fig. 1.
flow rate for the separation was 1.2 mI/mm. After one minute,
the %B was increased in a linear function to 22% over a four
minute interval. Over the next minute, the %B was increased in
a linear fashion to 36%, then allowed to run isocratically for an
additional 14 minutes. Under these conditions, the retention
times for 12-HETE and 12-hydroperoxyeicosatetraenoic acid
were 14.8 and 16.7 minutes, respectively.
The column effluent was monitored from 200 to 310 nm, and
the products in the sample were identified by their retention
times as compared to the retention times of known standards,
and by their UV absorbance spectra. Mass was calculated as
described previously.
Glomerular isolation and LTB4 generation
Three hours after the injection of anti-GBM antibodies, rats
were anesthetized and their kidneys removed and placed in
phosphate buffered saline (PBS) with 20 m Hepes (pH 7.2).
Glomeruli were isolated as previously described [9], and then
permeabilized with 10 U/mI collagenase and 10 U/ml DNase in
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Table 1. Effect of SK&F 107649 (200 mg/kg) and normal sheep antibodies on renal function in rats
BUN PCr
Ccr
ml/min/100 g
UV
m1124
hr/l00 g
UpV
mg/min/C,
FENa FEurea
mg/dl %
Control 13.6 0.8 0.53 0.01 0.59 0.02 7.7 0.4 0.002 0.0004 0.97 0.02 105.2 4.0
SK&F 107649 10.5 0.6° 0.51 0.02 0.38 0.03° 7.5 1.1 0.003 0.0006 0.88 0.05 138.0 8.5a
200 mg/kg
Normal sheep antibody 14.3 1.3 0.53 0.03 0.62 0.04 8.1 0.5 0.002 0.0003 0.99 0.06 113.1 8.5
27 mg/kg
Abbreviations are: UV, urinary protein excretion; UV, flow.
a P < 0.05 vs. control; N = 12
SK&F1 07649, mg/kg
Fig. 6. Effect of orally administered SK&F 107649 on cx vivo whole
LTB4 production. Three hours after SK&F 107649 administration,
whole blood was removed and stimulated with the calcium ionophore,
A23 187. The blood was extracted and LTB4 was measured as described
in the Methods. Data presented are the mean SEM, N 6. In some
cases the SEM was small and obscured by the size of the symbol. *P <
0.05 compared to vehicle controls.
Krebs-Henseleit (K-H) buffer (120 mr'i NaCl, 4.7 m'vi KC1, 1.2
mM KH2PO, 25 ma'i NaHCO3, 1.2 mM MgC1, 2.5 mM CaCI2
and 10 m dextrose at pH 7.4) for 20 minutes at room
temperature. To remove released arachidonic acid and reduce
basal prostaglandin and leukotriene production, the glomeruli
were incubated with 0.1% fatty acid free bovine serum albumin
for 10 minutes. The glomeruli were washed with K-H buffer
then incubated for 30 minutes at 37°C with constant agitation for
determination of baseline LTB4 production. Following two
washes with K-H buffer, the glomeruli were stimulated with 10
LM ionomycin and 10 .tM arachidonic acid in K-H buffer for 30
minutes at 37°C. Glomerular protein was determined by the
method of Lowry et al [10]. LTB4 was measured in the
unextracted glomerular supernatant by radioimmunoassay
(RIA). Briefly, LTB4 antiserum [cross reactivities at 50% dis-
placement were 6% for 5(S), l2(S)-DiHETE and <0.01% for
20-OH-LTB4, 20-COOH-LTB4, LTB4, and LTE4] was diluted 1
to 1,750 in LTB4 RIA buffer (50 m Tris buffer (pH 7.3)
containing 0.8% NaC1 and 0.1% gelatin]. Samples or standards
(diluted in K-H buffer), LTB4 antiserum and tritiated LTB4
(diluted in RIA buffer) were incubated overnight at 4°C. A 0.5%
dextran and 0.5% charcoal mixture was used to separate the
0 50 100 150 200
SK&F1 07649, mg/kg BID
Fig. 7. Effect of SK&F 107649 on the anti-GBM antibody-mediated
changes in BUN (A) and Pcr (B). SK&F 107649, at the indicated doses,
was given orally 30 minutes before and 6 hours after anti-GBM antibody
(27 mg/kg) administration. Twenty-four hours after antibody injection,
plasma was obtained and BUN and Cr measured. Data presented are
the mean SEM, N  6. < 0.05 compared to vehicle control.
antibody-bound LTB4 from unbound LTB4. The supernatant
containing the tritiated LTB4-antibody complex was added to
scintillation fluid (Ready Safe, Beckman Instruments, Inc.,
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Fig. 8. Effect of SK&F 107649 on the anti-GBM antibody-mediated
effects on C (A) and urine protein excretion corrected for C. (B).
Experimental protocol was as described for Fig. 6. GFR was deter-
mined using creatinine clearance measured over a 24 hour interval.
Protein was assayed in urine collected for 24 hours after antibody
injected and corrected for GFR. Data presentation and statistics are as
described for Fig. 6.
Fullerton, California, USA) and counted in an automatic liquid
scintillation counter (ICN Micromedic Systems, Inc., Hunts-
ville, Alabama, USA).
Statistics
Data are presented as mean SEM. Statistical analysis of the
cell counts between any of the groups was assessed by one-way
analysis of variance, followed by pairwise comparisons, utiliz-
ing a P value (0.05) calculated by the Bonferroni method.
Statistical analysis of the data were performed using the
Kruskal-Wallis nonparametric procedure, followed by nonpa-
rametric comparisons [11].
Results
Effect of anti-GBM antibody administration on renal function
At doses of 5 to 15 mg/kg, anti-GBM antibodies did not
significantly inhibit GFR as determined by 24 hour creatinine
clearance (Fig. 2). However, at doses of anti-GBM antibodies at
or exceeding 20 mg/kg, GFR was decreased significantly.
Administration of anti-GBM antibodies at a dose of 10 mg/kg
resulted in a small, but significant (P < 0.05) increase in 24-hour
urinary protein excretion (Fig. 3A). Protein excretion was
dramatically increased at a dose of 15 mg/kg of anti-GBM
antibodies. At higher doses (20 to 30 mg/kg), anti-GBM anti-
bodies caused no further increase in protein excretion. When
urinary protein excretion was calculated as a function of GFR,
there was a clear dose-dependent increase in protein excretion
(Fig. 3B).
Although there was a numerically significant increase in BUN
at doses of 5 and 10 mg/kg of antibody, these values fell within
the normal range for BUN in rats (Fig. 4A). P was unaffected
by anti-GBM antibodies up to a dose of 25 mg/kg, however,
higher doses (27 to 30 mg/kg) caused a significant increase in
both BUN and 1Cr (Fig. 4 A, B). Likewise, Feurea decreased
significantly at antibody concentrations above 25 mg/kg (Fig.
5A). FeNa was dose-dependently inhibited by increasing doses
of anti-GBM antibody (Fig. SB). Urine flow, whether evaluated
as ml/24 hr/100 g or as a percent of pretreatment urine flow, was
not dose-dependently affected by anti-GBM antibodies (results
not shown). A dose of 30 mg/kg of anti-GBM antibodies did,
however, cause a significant decrease in urine flow compared to
control (9.8 0.8 vs. 4.4 0.6 ml/24 hr/l00 g).
Normal sheep antibodies (27 pg/kg, i.v.) used as a negative
control did not significantly affect renal function in rats (Table
1).
Effect of anti-GBM antibody administration on glomerular
LTB4 production
To determine whether the anti-GBM antibodies used in these
studies caused an increase in glomerular LTB4 production,
glomeruli from control and anti-GBM antibody-treated rats
were examined. Three hours after the injection of 10 mg/kg of
anti-GBM antibodies, glomeruli were isolated and LTB4 pro-
duction was determined as described in the methods. Basal
level of LTB4 from glomeruli isolated from control rats in-
creased 19-fold after stimulation with 10 M ionomycin and 10
M arachidonic acid (13 1 vs. 244 18 pg/mg protein, P <
0.05). In glomeruli from anti-GBM-treated rats, basal LTB4
production increased approximately 30-fold with ionomycin
and arachidonic acid stimulation (17 7 and 497 26 pg/mg
protein, P <0.05). lonomycin- and arachidonic acid-stimulated
glomerular LTB4 production from anti-GBM-treated rats was
significantly higher than that from control rats.
Effect of SK&F 107649 on whole blood LTB4 and
thromboxane B2 production
To determine the effect of orally administered SK&F 107649
on LTB4 and thromboxane B2 production, an ex vivo assay was
employed. Three hours after the p.o. administration of various
concentrations of SK&F 107649, blood was withdrawn, pre-
pared as described in the Methods section and stimulated with
A23187. SK&F 107649 caused a dose-dependent inhibition of
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Table 2. Glomerular PMNs and glomerular immunofluorescence (IF)
Group
N of
rats
Injected
IgG
SK&F
107649
mg/kg
PMNs per
glomerulusa
Sheep
IgG
IF"
Rat
C3
IF
1 6 None — 0.14 0.03 — —
2 6 Anti-GBM (3 hr) 0 0.50 006d 3+ 1+
3 6 Anti-GBM (24 hr) 0 0.15 0.05 3+ 2+
4 6 Anti-GBM (3 hr) 200 0.40 0.17 3+ 1+
5 6 Anti-GBM (24 hr) 200 0.35 0.13 3+ 2+
6 6 Normal (24 hr) — 0.18 0.04 — —
a Mean values (± SEM) of 50 glomeruli per rat
b Linear staining with sheep anti-rat GBM
Granular staining with anti-rat C3
Significantly different from group 1 (P < 0.05)
LTB4 production (Fig. 6). Significant inhibition occurred at
doses of 100 mg/kg and greater. In comparison, SK&F 107649
at 200 mg/kg, did not significantly inhibit thromboxane produc-
tion (502 68 vs. 435 133 nmollsample). The effect of SK&F
107649 on eicosanoid production was also characterized in
human whole blood. In two separate experiments using A23 187-
stimulated whole blood, SK&F 107649 had an IC50 for LTB4
production of 1.1 and 1.3 M while for 12-HHT (a metabolite of
PGH2) production the IC50 was >10 and 100 M. In human
platelets, the IC50 for 12-HETE and l2-HPETE was 5.2 and 5.6
M.
Effect of SK&F 107649 on renal function in anti-GBM
antibody-treated rats
Treatment with SK&F 107649 caused a dose-dependent
decrease in the elevated BUN and Pcr in anti-GBM antibody
treated rats (Fig. 7 A, B). SK&F 107649 (100 to 200 mg/kg)
caused a significant decrease in both BUN and Cr At 200
mg/kg of SK&F 107649, the BUN and C, in anti-GBM anti-
body-treated rats were not significantly different from controls.
The anti-GBM antibody-induced fall in GFR was also attenu-
ated by SK&F 107649 in a dose-dependent fashion (Fig. 8A).
GFR was significantly improved at doses of SK&F 107649 at
and above 100 mg/kg. Although SK&F 107649 caused a de-
crease in urinary protein excretion, it remained significantly
elevated above control levels (Fig. 8B). SK&F 107649, at the
doses tested, did not significantly affect the anti-GBM antibody-
induced alterations in FENa or FErea. The effect of the highest
dose of SK&F 107649 (200 mg/kg) on renal function in control
rats is shown in Table 1.
Effect of anti-GBM antibodies on renal histology
By light microscopy, no morphologic alterations of the gb-
meruli could be detected between experimental and control
groups. At 3 hours and 24 hours, eosinophilic proteinaceous
casts were observed in many of the proximal and distal tubules
and collecting ducts, but there was no difference detected
between vehicle- or drug-treated groups. Quantitation of PMNs
revealed less than 1 PMN per glomerular crossection in all
groups (Table 2). Although there was a significant increase in
glomerular PMNs three hours after anti-GBM administration,
the number of PMNs at 24 hours was not different from
untreated rats or rats given normal sheep antibodies (Fig. 9).
SK&F 107649 did not reduce the influx of PMN seen at three
hours.
Immunofluorescence microscopy revealed diffuse linear dep-
osition for the sheep anti-rat GBM along the glomerular capil-
lary wall at 3 and 24 hours in rats given vehicle or SK&F
107649, with similar staining intensity between vehicle- and
drug-treated rats (Fig. 10 A, B). Likewise, segmental granular
deposition for rat C3 increased in intensity at 24 hours com-
pared to 3 hours, but was similar between vehicle- and drug-
treated rats at both intervals (Fig. 10 C, D).
Fig. 9. Choloroacetate esterase staining of kidney from (A) control rat injected with sheep JgG, or (B) rat injected with anti-GBM and killed 3
hours later. No increase in glomerular PMN infiltration (arrowheads) was observed following injection of anti-GBM compared to normal sheep IgG
(x540).
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Fig. 10. Immunofluorescent staining of anti-GBM in glomerulus of rats pretreated with vehicle (A) or SK&F 107649 (B) and killed 3 hours
following injection of anti-GBM. Diffuse, linear staining observed in drug-treated rat is similar to that observed in rat given vehicle.
Immunofluorescent staining of C3 in glomerulus of rats pretreated with vehicle (C) or SK&F 107649 (D) and killed 24 hours following injection of
anti-GBM. Segmental, granular staining observed in drug-treated rat is similar to that observed in rat given vehicle (x490).
Discussion
The anti-GBM model has proven useful in describing the
involvement of the immune system and arachidonic acid me-
tabolism in glomerulonephritis. In previous studies, investiga-
tors chose a dose of nephrotoxic antiserum which caused a
distinct detrimental effect on renal function. However, in the
absence of a well characterized dose-response relationship, it is
difficult to assess the impact of pharmacologic intervention in
this model. Accordingly, we modified the induction procedure
in order to obtain a reproducible dose-dependent decrease in
renal function in the rat. To this end, we isolated antibody from
anti-GBM antiserum using an affinity column, eliminating the
potential complicating immunologic effects associated with
injection of heterologous whole serum, Furthermore, to obtain
sufficient quantities of antibody to perform multiple experi-
ments with a standardized preparation of antibody, the eluates
from 12 columns totalling 1.51 g of purified immunoglobulin
were lyophiized, pooled and stored frozen in small aliquots to
eliminate refreezing the samples. In this way, we were able to
obtain reproducible dose-dependent effects on a variety of
parameters which were used to evaluate kidney function. The
dose-dependent responses, however, were not identical for all
parameters. For example, protein excretion, FENa and FErea
required a dose of 20 mg/kg of anti-GBM antibody to be affected
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significantly while BUN and 1Cr required a dose of 27 mg/kg to
be increased significantly. Because we wanted to examine the
effect of pharmacological intervention on all of these parame-
ters, a dose of 27 mg of antibody/kg was chosen to evaluate the
effects of the 5-LO inhibitor, SK&F 107649.
The rationale for using a 5-LO inhibitor in the anti-GBM
model is based on several lines of experimental results. In
glomeruli isolated from rats treated with anti-GBM serum,
5-LO products, such as LTB4 [1—3] and 5-HETE [1], are
increased. Furthermore, the addition of LTB4 exacerbates the
renal dysfunction caused by a low dose of anti-GBM antiserum
[5]. Several strategies which modulate the LO synthetic capac-
ity of glomeruli provide further circumstantial evidence for a
role of LO products in glomerulonephritis. Complement deple-
tion, which reduces glomerular LTB4, 5-HETE and 12-HETE
production in nephrotoxic serum-treated animals [1], also im-
proves GFR [4] and histopathology [1]. Dietary modification by
feeding rats an essential fatty acid deficient diet before treat-
ment with anti-GBM serum decreases glomerular LTB4 produc-
tion and also improves histology as well as decreases protein-
uria [3]. Although not definitive, these data are consistent with
the hypothesis that 5-LO products are involved in anti-GBM-
induced nephritis. To more directly determine the relationship
between elevated LO product formation and the detrimental
effect of nephrotoxic antibodies, the effect of 5-LO inhibition
was investigated in this model.
As described in this paper, 200 mg/kg of SK&F 107649
administered p.o. to rats inhibited LTB4, but not thromboxane
production in a whole blood ex vivo assay. In addition, the
inhibition of LTB4 was -100 X greater than the inhibition of
thromboxane synthesis in human whole blood and —5 X greater
than the inhibition of 12-LO products in human platelets. In
other studies not presented here, SK&F 107649 did not inhibit
PGE2 production by A23 187-stimulated human monocytes at
concentrations up to 30 LM, but had an ED50 of 1.8 LM for
inhibition of 5-LO activity from the isolated enzyme (personal
communications, Griswold). Using the methods described for
the rat studies, experiments done in mice show that SK&F
107649 has an ED50 of 9.9 mg/kg, p.o. for inhibition of LTB4
synthesis and 60 mg/kg, p.o. for inhibition of thromboxane
synthesis, These results indicate that SK&F 107649 is a selec-
tive 5-LO inhibitor in three different species. Whether or not the
inhibition of 12-LO observed ex vivo is demonstrable in vivo is
not known; however, this activity could also contribute to the
attenuation of glomerulonephritis.
The doses of SK&F 107649 used to study the effect of 5-LO
inhibition on renal dysfunction caused by anti-GBM antibody
administration were determined from the ionophore-stimulated
LTB4 production in ex vivo whole blood from rats. SK&F
107649 caused a dose-dependent improvement of the kidney
dysfunction associated with anti-GBM antibody treatment.
BUN and Cr were significantly reduced and GFR was signifi-
cantly increased by SK&F 107649. SK&F 107649 did not affect
the deposition of anti-GBM antibodies or rat C3 in this model of
nephrotoxic serum nephritis. Therefore, the protective effect of
SK&F 107649 was not related to reduced binding of anti-GBM
antibody. Although there was a significant increase in glomer-
ular PMN three hours after anti-GBM administration, SK&F
107649 did not significantly reduce the influx. This result,
however, is consistent with the inability of LTB4 to mediate
chemotactic activity in the rat [12]. The low numbers of
glomerular PMN observed in rats injected with 18 mg/kg of
anti-GBM antibodies may indicate that resident glomerular
cells, rather than PMNs, may be the source of increased
glomerular synthesis of LTB4 in this mild model of glomerulo-
nephritis.
On the basis of these experiments we conclude that 5-LO
products are, at least in part, responsible for the kidney
dysfunction mediated by anti-GBM antibodies in the rat. These
results provide good evidence that a specific 5-LO inhibitor
such as SK&F 107649 may prove beneficial in the treatment of
glomerulonephritis.
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Appendix. Abbreviations
5-LO, 5-lipoxygenase; GBM, glomerular basement membrane; BUN,
blood urea nitrogen; 1Cr, plasma creatinine; Cr, creatinine clearance;
FENa, fractional excretion of sodium; FEurea, fractional excretion of
urea; LT, leukotriene; GFR, glomerular filtration rate; PMN, polymor-
phonuclear cells; HETE, hydroxyeicosatetraenoic acid; PG, pros-
taglandin; HilT, hydroxyheptadecatrienoic acid; and PBS, phosphate
buffered saline.
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